A Type D meeting was held with the FDA in March 2025 to discuss the potential regulatory path for OPGx-LCA5, including the ...

Q1 2025 Earnings Call Transcript May 14, 2025 Operator: Greetings, and welcome to the Alcon First Quarter 2025 Earnings Call.

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...